Continued undertreatment of older men with localized prostate cancer

Urology

Volumn 62, Issue 5, 2003, Pages 860-865

  Schwartz, Kevin L ^b   Alibhai, Shabbir M H ^a   Tomlinson, George ^b   Naglie, Gary ^b   Krahn, Murray D ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; COHORT ANALYSIS; COMORBIDITY; DATA ANALYSIS; DEMOGRAPHY; DISEASE ASSOCIATION; ELDERLY CARE; HEALTH CARE QUALITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY ADJUSTED LIFE YEAR; REVIEW; SCORING SYSTEM; STATISTICAL MODEL;

EID: 0242495789     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00690-3     Document Type: Article

References (30)

1. Jemal A., Thomas A., Murray T., et al. Cancer statistics, 2002. CA Cancer J Clin. 52:2002;23-47.
2. Albertson P. A 72-year-old man with localized prostate cancer. JAMA. 274:1995;69-70.
3. Albertson P.C., Fryback D.G., Storer B.E., et al. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol. 156:1996;127-132.
4. Alibhai S.M.H., Krahn M.D., Cohen M.M., et al. Older patients receive less aggressive treatment for clinically localized prostate cancer. Clin Invest Med. 23:2000;332-333. (abstract).
5. Krahn M.D., Bremner K.E., Asaria J., et al. The 10-year rule revisited accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology. 60:2002;258-263.
6. Alibhai S.M.H., Naglie G., Nam R., et al. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol. 21:2003;3318-3327.
7. Alibhai SMH: Do Age and Comorbidity Influence the Treatment of Localized Prostate Cancer? (MSc thesis). Toronto, University of Toronto, 2001.
8. Bennett C.L., Greenfield S., Aronow H., et al. Patterns of care related to age of men with prostate cancer. Cancer. 67:1991;2633-2641.
9. Krahn M, Ritvo P, Irvine J, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care 41(1): 153-164, 2003.
10. Statistics Canada. Life tables, Canada and Provinces. Health Reports 2(suppl 13): 17-18, 1990.
11. Holmberg L., Bill-Axelson A., Helgesen F., et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 347:2002;781-789.
12. Lau H.Y., Angyalfi S.J. Radiation therapy for localized prostate cancer strategies and future directions. Ann R Coll Physicians Surg Can. 34:2001;149-156.
13. Catton C., Gospodarowicz M., Mui J., et al. Clinical and biochemical outcome of conventional dose radiotherapy for localized prostate cancer. Can J Urol. 9:2002;1444-1452.
14. Lu-Yao G.L., Yao S.-L. Population-based study of long-term survival in patients with clinically localized prostate cancer. Lancet. 349:1997;906-910.
15. Chodak G.W., Thisted R.A., Gerber G.S., et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 330:1994;242-248.
16. Gerber G.S., Thisted R.A., Scardino P.T., et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA. 276:1996;615-619.
17. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer a multi-institutional pooled analysis. JAMA. 34:1999;525-546.
18. Guidelines on the management of prostate cancer. BJU Int. 84:1999;987-1014.
19. Krahn M.D., Naglie G., Naimark D., et al. Primer on medical decision analysis part 4 - analyzing the model and interpreting the results. Med Decis Making. 17:1997;142-151.
20. Harrell F.E. Jr, Lee K.L., Mark D.B. Multivariable prognostic models issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 15:1996;361-387.
21. Yan Y., Carvalhal G.F., Catalona W.J., et al. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer. 88:2000;1122-1130.
22. Fleshner N., Rakovitch E., Klotz L. Differences between urologists in the United States and Canada in the approach to prostate cancer. J Urol. 163:2000;1461-1466.
23. Fowler F.J. Jr, McNaughton Collins M., Albertson P.C., et al. Comparisons of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA. 283:2000;3217-3222.
24. Fleming C., Wasson J.H., Albertsen P.C., et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA. 269:1993;2650-2658.
25. Kattan M.W., Cowen M.E., Miles B.J. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med. 12:1997;299-305.
26. Cowen M.E., Miles B.J., Cahill D.F., et al. The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. Med Decis Making. 18:1998;376-380.
27. Singer P.A., Tasch E.S., Stocking C., et al. Sex or survival trade-offs between quality and quantity of life. J Clin Oncol. 9:1991;328-334.
28. Pickles T., Coldman A., Phillips N. The changing face of prostate cancer in British Columbia 1988-2000. Can J Urol. 9:2002;1551-1557.
29. Moul J.W., Wu H., Sun L. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery. 132:2002;213-219.
30. Bubolz T., Wasson J.H., Lu-Yao G., et al. Treatments for prostate cancer in older men 1984-1997. Urology. 58:2001;977-982.